Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsLong-term efficacy and safety of raltegravir in the management of HIV infection.Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trialsClinical use of HIV integrase inhibitors: a systematic review and meta-analysisEffectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed ViremiaHIV integrase inhibitors: a new era in the treatment of HIV.Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patientsEffects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Inflammation, Immune Activation, and Antiretroviral Therapy in HIV96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapyHIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular studyTreatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Epidemiology and management of antiretroviral-associated cardiovascular disease.Role of raltegravir in the management of HIV-1 infection.Switching antiretroviral therapy to minimize metabolic complications.Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone.Management of the metabolic effects of HIV and HIV drugs.Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.Can Metabolic Factors be used Prognostically for Short-Term Mortality in HIV-Infected Patients?Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.Integrase inhibitors in the treatment of HIV-1 infection.Cost-effectiveness of raltegravir in HIV/AIDS.Clinical management considerations for dyslipidemia in HIV-infected individuals.Role of raltegravir in HIV-1 management.Effect of darunavir on lipid profile in HIV-infected patients.Next-generation integrase inhibitors : where to after raltegravir?Raltegravir as antiretroviral therapy in HIV/AIDS.Drug safety profile of integrase strand transfer inhibitors.
P2860
Q24628743-8971CE66-4B09-4667-BFC2-489CB96647AEQ27686870-3A04FBA1-D4AE-4DE5-BD78-D6FD4F651468Q28476822-8F8FE2B1-FBAE-4A32-B630-D181C9C6AB3FQ28484930-18C6258A-1D2C-453B-9D84-AD6FB555D44DQ28548630-8CEEE83B-21D9-4CAF-A86E-F19C19C67E48Q30956943-BA06FB4C-2F2B-4F2E-8701-8F40EF9DFE0FQ33787675-545B7AE1-1701-4AD7-B0D0-B6B002D1E2E7Q33880418-48FBE8FC-165B-4847-A7CA-B685C74C32A6Q33912595-7FDEB833-AA39-4F3D-8B2E-2D995DB34349Q34341541-5DA6798F-4589-4A87-B71D-8D52CDAFB7C5Q34713094-0DC23942-20BB-495C-A0BA-F9A0B81BF892Q35023687-2297BCF7-B8F1-4811-8B98-7B9A3E7923F5Q35026582-4355627A-AF62-49C8-9682-0938BDB90606Q35035055-788EF1DC-D206-44F3-AF3F-B94A4DB3D6D9Q35106654-90B98015-4AA0-497C-967B-59C954827349Q35147189-01F41F6A-77AE-479C-8AD2-46AA84D455F4Q35338096-9A520F1F-646B-45DB-BD4E-A15C8A9EE9CCQ35557318-FCA9BBEB-D12A-40C5-9931-191730B901F3Q35608074-FC892E46-35A4-488C-8867-7BFD334BBBFFQ35789343-04E49FF5-AB7A-49C0-A735-0B260BDA646FQ35965242-C9167EF4-799A-4EA6-8865-E3F3685D6E41Q35995856-46A8DA6D-6EA3-4C3B-98F4-4CDF34478212Q36021411-F8CF193D-3F4B-44B4-B188-4EC95363FD63Q36051942-2F60F871-EEB6-4F66-8F08-AD4BC0103B2DQ36250418-DEA7CFE4-448B-4390-88F0-5046AEFED70EQ36320322-2D05BD2F-5655-430B-9F1E-AA51DE864545Q36426953-34150417-025E-4B1E-9FC9-FB4065940691Q36553976-26E54EEF-75AF-4EBE-9372-92FC8E4825E3Q36612849-351CA846-166B-48E9-ACB7-0AA48855C62CQ36839676-4407D302-34DB-4A7F-BCB6-79AC95967DACQ37418140-92DD7E17-2BDC-4E0F-BB02-0AF9D3381564Q37779319-3074594F-97F8-4141-856E-3AB66FC8E949Q37790212-1CFD446E-4A60-4490-93CD-54F967E643E8Q37958046-A49F28E3-4CB7-4C66-BD5C-69B9D47C133FQ37982205-5A8AA066-A0D0-40B0-8815-EA74DF5A4722Q38002011-6E4A0227-B299-4B28-BE26-68F4106A307BQ38058385-753F97CB-F3BE-457C-8BDF-0CDED1585657Q38081866-D0FE50EE-C938-40A9-B12C-2697BB3035A5Q38168587-8EA7058D-F92B-47F7-87EE-13E60C67387CQ38193524-47577102-3C96-4EDA-8E3C-BE4B5BCCFC21
P2860
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@en
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@nl
type
label
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@en
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@nl
prefLabel
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@en
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@nl
P2093
P1433
P1476
Substitution of raltegravir fo ...... ed patients: the SPIRAL study.
@en
P2093
Antonio Antela
Esteban Martínez
Felix Gutiérrez
Ignacio Pérez
Javier Murillas
Josep M Llibre
José M Gatell
Juan Berenguer
Judit Pich
Maria Saumoy
P304
P356
10.1097/QAD.0B013E32833A608A
P407
P577
2010-07-01T00:00:00Z